Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.
Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.
Transcript (slightly modified)
When a new reimbursement model is being developed, at what stage should providers become involved?
My goal is that we should be involved from day 1. I was in practice for almost 20 years before joining Aetna, and the last time that I spoke to a provider as on oncologist was when they were denying some type of care plan that I was requesting. So, this is a 360-degree change. We communicate and collaborate together. I feel that from a provider perspective and with our oncology medical home models, which parallel the oncology care model, we should work together on coming up with what the ideal payment plan is going to be, and that’s our goal.
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL
March 25th 2024The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).
Read More